The company operates in two segments: Software, which transforms molecular discovery for life sciences and materials science industries, and Drug Discovery, which focuses on building a portfolio of preclinical and clinical programs internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger's technology platform combines physics-based modeling and machine learning to accelerate innovation in pharmaceutical and materials design.
Cyborg Score Rationale
Schrödinger is a profitable public company with a dominant physics-based computational platform used by major pharma and biotech players. Dual revenue streams (software licensing and drug discovery) provide stability, and strategic partnerships with Novartis strengthen pipeline prospects. However, modest market cap (~$1.1B as of June 2026) and a competitive field of AI-driven drug discovery competitors limit upside potential.
Top Insights
The majority of the company's revenue is derived from the Software segment.
Schrödinger has approximately 800 employees and is engaged with customers and collaborators in more than 70 countries.
Schrödinger's partners include pharmaceutical companies including Bayer and Takeda, and heavy industries including Boeing and Sabic.
Schrödinger's FEP+ software is considered a gold standard computational tool for designing high-quality drug candidates.
Named Competitors
Isomorphic Laboratories — AI-driven structure prediction for drug discovery
Insilico Medicine — AI platforms for multi-omics target discovery and automated drug design
Citrine Informatics — AI platform for materials discovery and optimization
Recursion Pharmaceuticals — Computational biology platform for drug discovery
Recent Developments
(April 2026) Schrödinger presenting on materials science applications at UTECH Europe, demonstrating platform capabilities in polymer discovery.
(May 2024) Schrödinger made a later-stage venture investment in Ajax Therapeutics.
(August 2022) Schrödinger exited its investment in Structure Therapeutics.
Open the full interactive Schrödinger, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.